Celltrion Sets Up JV With Nan Fung To Sell Biosimilars In China

Celltrion is pushing into biosimilar market opportunities in China by setting up a joint venture with local player Nan Fung Group. Vcell Healthcare is aiming to market three of Celltrion’s biosimilars as well as exploring setting up a manufacturing plant in China.

China - South Korea
Korea’s Celltrion has linked up with China’s Nan Fung Group • Source: Shutterstock

Celltrion has struck a deal with Hong Kong’s Nan Fung Group to establish a local joint venture for developing and marketing biosimilars under the banner of Vcell Healthcare Limited.

“At the formation of the joint venture,” the companies announced, “Vcell Healthcare Limited has simultaneously signed a licensing agreement with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business